Merck reports positive results for blockbuster cancer drug in treating non-small cell lung cancer

Keytruda showed a 'statistically significant and clinically meaningful improvement' in overall survival in a late-stage trial.

Related Keywords

,European Society For Medical Oncology Congress ,Merck Research Laboratories ,Merck Co ,European Society ,Medical Oncology Congress ,Marjorie Green ,Article Normal ,Pharmaceuticals ,Cancer Drugs ,Healthcare Life Sciences ,Specialized Drugs Medications ,Regulation Government Policy ,New Products Services ,Research Development ,Corporate Actions ,Corporate Industrial News ,Products Services ,New Product Service Testing ,Cancer ,Political General News ,Chemotherapy Radiotherapy Immunotherapy ,Respiratory Tract Diseases ,Health ,Respiratory Tract Cancer ,Medical Conditions ,Medical Treatments Procedures ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Merck Amp Co Inc ,Mrk ,S Amp Ampp 500 Index ,Spx ,Regulation ,Government Policy ,New Products ,Services ,Research ,Development ,Corporate ,Industrial News ,Products ,New Product ,Service Testing ,Political ,General News ,Chemotherapy ,Radiotherapy ,Immunotherapy ,Medical Treatments ,Procedures ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,